HydroGraph Clean Power uses proprietary detonation technology to produce high-purity graphene cost-effectively through its Hyperion System. The company has secured key regulatory approvals and is expanding production in Texas while growing its partner network. Despite holding $42.8 million in cash, HydroGraph remains pre-revenue and reported a $6.97 million net loss, relying on equity financing. The company faces significant risks in execution and commercialization but offers a speculative buy opportunity for long-term investors interested in advanced materials if it successfully scales and wins commercial contracts.
The global therapeutic apheresis market, valued at $3.84 billion in 2025, is projected to grow to $8.94 billion by 2035 at a 7.9% CAGR. Growth is fueled by rising chronic and autoimmune diseases, advances in automated apheresis technology, and expand...
Aduro Clean Technologies completed a private placement raising C$9.16 million by selling 431,884 shares at C$21.20 each. The funds will support technology development, marketing activities, working capital, and general corporate needs. The offering w...
Aduro Clean Technologies completed a private placement raising approximately C$9.16 million by selling 431,884 common shares at C$21.20 each. The funds will support technology development, marketing, working capital, and general corporate purposes. T...
Mesoblast Limited has drawn $50 million from a new five-year loan facility provided by a shareholder, replacing higher-cost short-term debt. This move strengthens Mesoblast's balance sheet by lowering interest costs and removing short-term obligation...
HUTCHMED announced positive Phase II trial results for fanregratinib in treating advanced intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement. The study showed a 42.5% objective response rate and median overall survival of 16.6 mont...
